As summarized in Table 1, correlation analysis between IGF2BP3 expression and clinicopathologic characteristics of the 28 HSCC patients showed that high IGF2BP3 expression did not correlate with tumor size (P>0.05), tumor grade (P>0.05), or tumor-node-metastasis (TNM) stage (P>0.05). This evidence concerns the gene IGF2BP3 and neoplasm.